Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...

Eli Lilly er danske Novo Nordisks største konkurrent på medicinalmarkedet inden for diabetes og overvægt. Novo ...

Novo Nordisk reported strong sales growth for its Wegovy and Ozempic drugs, while its 2025 guidance topped expectations. Shares in Novo, one of Europe's largest listed companies, rallied in the U.S.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

In its outlook for 2025, Novo Nordisk has predicted 'continued periodic supply constraints and related drug shortage ...

drugmaker Novo Nordisk said Tuesday. (CNN) — Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug ...

Lægemiddelstyrelsen i USA, FDA, har tirsdag godkendt Novo Nordisks diabetesmiddel Ozempic til behandling af kronisk ...

Det er USA's føderale fødevare- og lægemiddelmyndighed (FDA), der har godkendt medicinen, som er blevet udviklet og bliver solgt af Novo Nordisk. Dermed kan lægemidlet bruges til at behandle endnu ...

Novo Nordisk said the Food and Drug Administration approved the diabetes-drug Ozempic to be used to help kidney-disease patients. Ozempic, or semaglutide, can now be used to reduce the risk of ...

make Ozempic the most broadly indicated drug in its class, with the largest set of specific medical conditions that it may be prescribed to treat.Novo Nordisk is conducting a different study to ...